Men in highest quintile of plant-based dietary index had significantly lower risk for prostate cancer progression and recurrence<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Feb. 16, 2023 (HealthDay News) — Plant-based diets are associated with a reduced risk for prostate cancer (PC) progression and recurrence, according to a study presented at the American Society of Clinical Oncology annual Genitourinary Cancers Symposium, held from Feb. 16 to 18 in San Francisco.<\/p>\n
Vivian N. Liu, from the University of California in San Francisco, and colleagues examined 2,038 men diagnosed with T1 to T3a PC who had completed a food frequency questionnaire a median of 31.5 months after diagnosis. Overall and healthy plant-based dietary indices (PDI and hPDI, respectively) were calculated, and the associations with PC progression and recurrence were examined.<\/p>\n
The researchers identified 204 progression events during a median follow-up of 7.4 years; 169 were due to biochemical recurrence. Compared with men in the lowest quintile of PDI, those in the highest quintile had a significantly lower risk for PC progression and recurrence (hazard ratios, 0.48 and 0.47, respectively). hPDI was not associated with PC progression or recurrence overall, but a significant reduction in the risk for recurrence was seen for men in the higher quintiles. Greater consumption of a healthful plant-based diet was associated with a lower risk for PC recurrence among men aged 65 years or older (hazard ratio, 0.41). Furthermore, among those with a brisk\/fast walking pace, the risk for progression and recurrence was lower for men in the highest PDI quintile (hazard ratios, 0.33 and 0.41, respectively).<\/p>\n
“We’ve known that diets that include vegetables, fruits, legumes, and whole grains are associated with numerous health benefits, including a reduction in diabetes, cardiovascular disease, and overall mortality,” Liu said in a statement. “We can now add benefits in reducing prostate cancer progression to that list.”<\/p>\n
Several authors disclosed financial ties to the biopharmaceutical industry.<\/p>\n
Press Release<\/a><\/p>\n